Constructing a pancancer ubiquitination regulatory network to determine tumor characteristics, immunotherapy response, and prognosis
Journal for ImmunoTherapy of Cancer · 2025
DOI: 10.1136/jitc-2025-012539 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Zheng Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Ubiquitination, Immunotherapy, Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Special Research Fund for Central Universities, Peking Union Medical College, National Natural Science Foundation of China, the Special Fund of the China Cancer Research Foundation/Beijing Hope Marathon.
Abstract (Originalsprache)
Background
Ubiquitination—a pivotal post-translational modification that orchestrates cellular homeostasis and oncogenic pathways—remains underexplored as a pancancer regulatory hub. Although ubiquitination dysregulation is linked to tumor progression, a comprehensive, multicancer framework integrating prognostic, molecular, and microenvironmental landscapes is lacking.
Methods
This study integrated data of 4,709 patients from 26 cohorts across five solid tumor types (lung cancer, esophageal cancer, cervical cancer, urothelial cancer, and melanoma) and mapped the molecular profiles to the interaction network. Cox regression and the Kaplan-Meier survival method were employed for prognostic analysis. Functional enrichment and protein–protein interaction analyses were performed to identify the key downstream pathways and genes. Findings were validated using independent patient cohorts, cell line models, and in vivo experiments.
Results
Key nodes and prognostic pathways within the ubiquitination-modification network were identified. A conserved ubiquitination-related prognostic signature (URPS) effectively stratified patients into high-risk and low-risk groups with distinct survival outcomes across all analyzed cancers. URPS may serve as a novel biomarker for predicting immunotherapy response, with the potential to identify patients who are more likely to benefit from immunotherapy in clinical settings. A comprehensive analysis of URPS-associated proteins revealed novel cancer-related interaction partners as potential drug targets. At the single-cell resolution, URPS enabled more precise classification of distinct cell types and was associated with macrophage infiltration within the tumor microenvironment. In vivo, in vitro, and patient cohort analyses, demonstrated that OTUB1-TRIM28 ubiquitination plays a crucial role in modulating MYC pathway and influencing patient prognosis.
Conclusion
We constructed a pancancer ubiquitination regulatory network and prognostic model, revealing important pathways, and offering insights into predicting patient prognosis and understanding biological mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing, Chin…
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Institute of Cancer Research, Henan Academy of Innovations in Medical Sciences, Zhengzhou, Henan, China.
Förderung
- the Special Research Fund for Central Universities, Peking Union Medical College
- National Natural Science Foundation of China
- the Special Fund of the China Cancer Research Foundation/Beijing Hope Marathon
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
- the CAMS Innovation Fund for Medical Sciences
Zitieren
APA
Zhou, Z., Wang, B. Z., Zhang, C., Zhang, G., Wu, P., Dong, X., Sun, N., & He, J. (2025). Constructing a pancancer ubiquitination regulatory network to determine tumor characteristics, immunotherapy response, and prognosis. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-012539
Vancouver
Zhou Z, Wang BZ, Zhang C, Zhang G, Wu P, Dong X, et al. Constructing a pancancer ubiquitination regulatory network to determine tumor characteristics, immunotherapy response, and prognosis. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2025-012539
BibTeX
@article{Zhou2025,
author = {Zhou, Zheng and Wang, Bing-Zhi and Zhang, Chaoqi and Zhang, Guochao and Wu, Peng and Dong, Xin and Sun, Nan and He, Jie},
title = {Constructing a pancancer ubiquitination regulatory network to determine tumor characteristics, immunotherapy response, and prognosis},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
doi = {10.1136/jitc-2025-012539}
}
EUVIMED